Gillies O'Bryan-Tear

Gillies has over 30 years of experience in the pharmaceutical industry, spanning clinical development, medical management, and commercial roles. In 2009 he became Chief Medical Officer of Algeta, a listed Norwegian biotech company developing a radiopharmaceutical for prostate cancer, which was subsequently acquired in 2014 by Bayer. Following the acquisition, Dr. O'Bryan-Tear has been a retained adviser to a number of global biotechnology companies including Audentes, Fusion Pharmaceuticals, and Clarity Pharmaceuticals. Gillies is a Fellow of the Faculty of Pharmaceutical Medicine in the UK and is Chair of its Policy and Communications Group, as well as a Fellow of the Royal College of Physicians. He obtained his MD degree from the University of Cambridge and University College Hospital, London, and trained in internal medicine and oncology in the UK.